Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The company’s board of directors hasn’t made a final decision to proceed with the listing.
Domain Therapeutics announces that it has secured a €3.5M investment from existing shareholder Seventure Partners, to accelerate its next growth phase.
MorphoSys AG will present at the following conferences
Stoke focuses on treating genetic diseases by upregulating protein expression. Its lead compound, STK-001, is focused on Dravet syndrome, a rare form of epilepsy that starts in infancy.
ADL Bionatur Solutions recently reported Q119 results, showing positive €0.11m EBITDA, and over 134% year-on-year revenue growth to €10m, driven by 180% growth in contract manufacturing.
Polarean Imaging plc, the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging market, announces it will be hosting a Capital Markets Day for all investors on Wednesday 12 June 2019.
Auris Medical Holding Ltd. provided a business update, including a review of recent clinical, regulatory and operational highlights and progress.
InflaRx reported financial and operating results for the first quarter ended March 31, 2019.
Medtronic plc announced financial results for its fiscal year and fourth quarter 2019, which ended April 26, 2019.
All Resolutions Proposed by the Company’s Management Approved